Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2012

View Archived Issues

GLA screened for adjuvant efficacy in an experimental malaria model

University of Michigan patents novel antibodies binding to integrin alpha-2

Roche and Siena Biotech synthesize novel beta-secretase inhibitors

Cat-PAD proves safe and effective in cat allergic subjects

Treatment begins in first phase II trial of IPH-2102 for AML

Japanese researchers present novel adenovirus vectors for cancer

Ajou University discloses novel adult stem cell lines

Spanish researchers synthesize new protein kinase inhibitors

Bayer Intellectual Property describes novel MKNK1 inhibitors

New RNA-directed RNA polymerase inhibitors divulged by Roche

Amakem prepares novel protein kinase inhibitors

Amarin completes dosing in fixed-dose Vascepa/statin study

Ironwood Pharmaceuticals and Forest Laboratories launch Linzess

Alexza's MAA for Adasuve receives positive opinion from EMA advisory committee

Intracellular mechanisms of glycolysis-mediated tumor growth discovered

Helix and Merck & Co. terminate agreement on topical interferon alfa-2b products

Roche's Perjeta receives CHMP recommendation for approval

LX-1033 receives fast track status from the FDA

Evotec licenses portfolio of NMDA antagonists to Janssen

Phenex collaborates with Janssen on autoimmune and chronic inflammatory disorders

E-selectin inhibitor GMI-1271 shows promise in vivo

MedImmune to develop therapies against serious bacterial infections

Boehringer Ingelheim's anti-CD33 MAb enters phase I AML study

Vivalis and Intercell agree to merge

Lundbeck to divest non-core products to Recordati

Invion reports on pre-IND meeting for INV-103

Fibrocell Science to begin phase II azficel-T trial for restrictive burn scars

GSK's four-strain seasonal influenza vaccine Fluarix Quadrivalent approved for use in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...